Comparative Pharmacology
Head-to-head clinical analysis: BIPHETAMINE 7 5 versus RITALIN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIPHETAMINE 7 5 versus RITALIN SR.
BIPHETAMINE 7.5 vs RITALIN-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
20 mg orally twice daily, typically 30-45 minutes before breakfast and lunch; maximum 60 mg/day.
None Documented
None Documented
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
2-3 hours for the immediate-release component; sustained-release formulation shows biphasic elimination with terminal half-life of 2-4 hours.
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (pH <5.6) increases excretion; alkaline urine (pH >7.0) decreases it.
Primarily renal (90%) as metabolites including ritalinic acid, with 1-3% unchanged; minor biliary/fecal elimination.
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant